Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors

References

• Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385–403.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. JCO. 2010;28:1061–1068.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (London, England). 2011;378:1931–1939.
   PubMed Web of Science ®Google Scholar
• Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66:1160–1178.
   PubMed Web of Science ®Google Scholar
• Lankhorst S, Saleh L, Danser AJ, et al. Etiology of angiogenesis inhibition-related hypertension. Curr Opin Pharmacol. 2015;21:7–13.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events v4.0. National Cancer Institute; 2009.
   Google Scholar
• Bellinger AM, Arteaga CL, Force T, et al. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation. 2015;132:2248–2258.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457–1467.
   PubMed Web of Science ®Google Scholar
• Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129–1136.
   PubMed Web of Science ®Google Scholar
• Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008;100:282–284.
   PubMed Web of Science ®Google Scholar
• Vigneau C, Lorcy N, Dolley-Hitze T, et al. All anti-vascular endothelial growth factor drugs can induce ‘pre-eclampsia-like syndrome’: a RARe study. Nephrol Dial Transplant. 2014;29:325–332.
   PubMed Web of Science ®Google Scholar
• Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123:2856–2869.
   PubMed Web of Science ®Google Scholar
• Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485:333–338.
   PubMed Web of Science ®Google Scholar
• Overexpression of vascular endothelial growth factor 165 (VEGF165) protects cardiomyocytes against doxorubicin-induced apoptosis. J Chemother. 2010;22:402–406.
   PubMed Web of Science ®Google Scholar
• Räsänen M, Degerman J, Nissinen TA, et al. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Proc Natl Acad Sci USA. 2016;113:13144–13149.
   PubMed Web of Science ®Google Scholar
• Pepe M, Mamdani M, Zentilin L, et al. Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy. Circ Res. 2010;106:1893–1903.
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhao W, Meng W, et al. VEGF-C/VEGFR-3 pathway promotes myocyte hypertrophy and survival in the infarcted myocardium. Am J Transl Res. 2015;7:697–709.
   PubMed Web of Science ®Google Scholar
• Di Lisi D, Madonna R, Zito C, et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. Int J Cardiol. 2017;227:11–17.
   PubMed Web of Science ®Google Scholar
• Ghatalia P, Morgan CJ, Je Y, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critic Rev Oncol/Hematol. 2015;94:228–237.
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–344.
   PubMed Web of Science ®Google Scholar
• Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis. 2010;53:114–120.
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci. 2005;26:119–124.
   PubMed Web of Science ®Google Scholar
• Katchman AN, Koerner J, Tosaka T, et al. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316:1098–1106.
   PubMed Web of Science ®Google Scholar
• Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation. 1996;93:407–411.
   PubMed Web of Science ®Google Scholar
• Kupershmidt S, Yang IC, Hayashi K, et al. The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB J. 2003;17:2263–2265.
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36:295–316.
   PubMed Web of Science ®Google Scholar
• Kramer B, Brill M, Bruhn A, et al. Relationship between the degree of coronary artery disease and of left ventricular function and the duration of the QT-interval in ECG. Eur Heart J. 1986;7:14–24.
   PubMed Web of Science ®Google Scholar
• Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res. 1994;28:933–946.
   PubMed Web of Science ®Google Scholar
• Davey PP, Barlow C, Hart G. Prolongation of the QT interval in heart failure occurs at low but not at high heart rates. Clin Sci. 2000;98:603–610.
   PubMed Web of Science ®Google Scholar
• Harada M, Tadevosyan A, Qi X, et al. Atrial fibrillation activates AMP-dependent protein kinase and its regulation of cellular calcium handling: potential role in metabolic adaptation and prevention of progression. J Am Coll Cardiol. 2015;66:47–58.
   PubMed Web of Science ®Google Scholar
• An MM, Zou Z, Shen H, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 2010;66:813–821.
   PubMed Web of Science ®Google Scholar
• Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncologica (Stockholm, Sweden). 2009;48:9–17.
   PubMed Web of Science ®Google Scholar
• Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:117–123.
   PubMed Web of Science ®Google Scholar
• Qi WX, Lin F, Sun YJ, et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol. 2013;71:431–439.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–630.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). 2014;383:31–39.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. JCO. 2012;30:3499–3506.
   PubMed Web of Science ®Google Scholar
• Donskov F, Michaelson MD, Puzanov I, et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer. 2015;113:1571–1580.
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763–773.
   PubMed Web of Science ®Google Scholar
• Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013;36:319–324.
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Cabanes L, et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. The Oncologist. 2011;16:1325–1332.
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. JCO. 2010;28:949–954.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. JCO. 2008;26:4672–4678.
   PubMed Web of Science ®Google Scholar
• Ryanne Wu R, Lindenberg PA, Slack R, et al. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009;40:101–108.
   PubMedGoogle Scholar
• Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227–230.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Douglas PS, Middleton JP, et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. The Oncologist. 2013;18:273–280.
   PubMed Web of Science ®Google Scholar
• Duffaud F, Sleijfer S, Litiere S, et al. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on european organisation for research and treatment of cancer (EORTC) 62043 and 62072 trials. Eur J Cancer (Oxford, England: 1990). 2015;51:2615–2623.
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–1239.
   PubMed Web of Science ®Google Scholar
• Schutz FA, Je Y, Azzi GR, et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22:1404–1412.
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Chuang J, et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncologica (Stockholm, Sweden). 2010;49:287–297.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. JCO. 2010;28:2280–2285.
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277–2285.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. JCO. 2011;29:1757–1764.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Je Y, Schutz F, et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013;87:80–89.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. JCO. 2011;29:632–638.
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (London, England). 2007;370:2011–2019.
   PubMed Web of Science ®Google Scholar
• Shamloo BK, Chhabra P, Freedman AN, et al. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Safety. 2012;35:507–518.
   PubMed Web of Science ®Google Scholar
• Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112:296–305.
   PubMed Web of Science ®Google Scholar
• Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009;15:7045–7052.
   PubMed Web of Science ®Google Scholar
• Polite BN, Sing A, Sargent DJ, et al. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012;118:1083–1090.
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199–206.
   PubMed Web of Science ®Google Scholar
• Selassie A, Wagner CS, Laken ML, et al. Progression is accelerated from prehypertension to hypertension in blacks. Hypertension (Dallas, TX: 1979). 2011;58:579–587.
   PubMed Web of Science ®Google Scholar
• Carson AP, Howard G, Burke GL, et al. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension (Dallas, TX: 1979). 2011;57:1101–1107.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhong B, Lun X, et al. Specific safety profile of bevacizumab in asian patients with advanced NSCLC: a meta-analysis. Medicine. 2015;94:e975.
   PubMed Web of Science ®Google Scholar
• Ueda T, Uemura H, Tomita Y, et al. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Japanese J Clin Oncol. 2013;43:616–628.
   PubMed Web of Science ®Google Scholar
• Lee SH, Bang YJ, Mainwaring P, et al. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Asia-Pac J Clin Oncol. 2014;10:237–245.
   PubMed Web of Science ®Google Scholar
• Chen Y, Suzuki A, Tortorici MA, et al. Axitinib plasma pharmacokinetics and ethnic differences. Invest New Drugs. 2015;33:521–532.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Li L, Shen F, et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014;111:1241–1248.
   PubMed Web of Science ®Google Scholar
• Sibertin-Blanc C, Mancini J, Fabre A, et al. Vascular endothelial growth factor a c.*237C > T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. Digest Liver Dis. 2015;47:331–337.
   Web of Science ®Google Scholar
• Etienne-Grimaldi MC, Formento P, Degeorges A, et al. Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol. 2011;71:921–928.
   PubMed Web of Science ®Google Scholar
• Morita S, Uehara K, Nakayama G, et al. Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2013;71:405–411.
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Moisse M, Delmar P, et al. Genetic markers of bevacizumab-induced hypertension. Angiogenesis. 2014;17:685–694.
   PubMed Web of Science ®Google Scholar
• Kim HR, Park HS, Kwon WS, et al. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013;72:825–835.
   PubMed Web of Science ®Google Scholar
• Kim JJVS, Elson P, Rini BI, Ganapathi MK, Ganapathi R. VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts). J Clin Oncol. 2009;27(15S Suppl):5005.
   Web of Science ®Google Scholar
• Eechoute K, van der Veldt AA, Oosting S, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 2012;92:503–510.
   PubMed Web of Science ®Google Scholar
• Huang CL, Kuo E. Mechanisms of disease: WNK-ing at the mechanism of salt-sensitive hypertension. Nat Clin Pract Nephrol. 2007;3:623–630.
   PubMedGoogle Scholar
• Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science (New York, NY). 2001;293:1107–1112.
   Google Scholar
• Newhouse S, Farrall M, Wallace C, Hoti M, Burke B, Howard P, etet al. Polymorphisms in the WNK1 gene are associated with blood pressure variation and urinary potassium excretion. PloS One. 2009;4:e5003.
   PubMed Web of Science ®Google Scholar
• Turner ST, Schwartz GL, Chapman AB, et al. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension (Dallas, TX: 1979). 2005;46:758–765.
   PubMed Web of Science ®Google Scholar
• Staruschenko A, Palygin O, Ilatovskaya DV, et al. Epidermal growth factors in the kidney and relationship to hypertension. Am J Physiol Renal Physiol. 2013;305:F12–F20.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng Y, Zhang W, et al. Polymorphisms of KDRGene are associated with coronary heart disease. J Am College Cardiol. 2007;50:760–767.
   PubMed Web of Science ®Google Scholar
• Kant R, Bali A, Singh N, et al. Prolyl 4 hydroxylase: a critical target in the pathophysiology of diseases. Korean J Physiol Pharmacol. 2013;17:111–120.
   PubMed Web of Science ®Google Scholar
• Chen Y, Dawes PT, Packham JC, et al. Interaction between smoking and polymorphism in the promoter region of the vegfa gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis. J Rheumatol. 2011;38:802–809.
   PubMed Web of Science ®Google Scholar
• Biselli PM, Guerzoni AR, de Godoy MF, et al. Vascular endothelial growth factor genetic variability and coronary artery disease in Brazilian population. Heart Vessels. 2008;23:371–375.
   PubMed Web of Science ®Google Scholar
• Howell WM, Ali S, Rose-Zerilli MJ, et al. VEGF polymorphisms and severity of atherosclerosis. J Med Genet. 2005;42:485–490.
   PubMed Web of Science ®Google Scholar
• Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002;13:260–264.
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrøm M, Brandslund I, et al. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2010;117:109–116.
   PubMed Web of Science ®Google Scholar
• Prior SJ, Hagberg JM, Paton CM, Douglass LW, Brown MD, McLenithan JC, etet al. DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol. 2006;290:H1848–H1H55.
   PubMed Web of Science ®Google Scholar
• Oh SY, Kwon HC, Kim SH, et al. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer. 2013;13:43.
   PubMed Web of Science ®Google Scholar
• Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5’-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51:1635–1639.
   PubMed Web of Science ®Google Scholar
• Ozvegy-Laczka C, Cserepes J, Elkind NB, et al. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updates. 2005;8:15–26.
   PubMed Web of Science ®Google Scholar
• Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004;65:1485–1495.
   PubMed Web of Science ®Google Scholar
• Shukla S, Robey RW, Bates SE, et al. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metabol Dispos. 2009;37:359–365.
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006;112:457–473.
   PubMed Web of Science ®Google Scholar
• Kim KA, Joo HJ, Park JY. ABCG2 polymorphisms, 34G > A and 421C > A in a Korean population: analysis and a comprehensive comparison with other populations. J Clin Pharm Ther. 2010;35:705–712.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Pasanen MK, Neuvonen PJ, et al. Different effects of the ABCG2 c.421C > A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009;10:1617–1624.
   PubMed Web of Science ®Google Scholar